Tweaking genes with CRISPR or viruses fixes blood disorders sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
A round-up of some of the key data from the annual American Society of Hematology (ASH) meeting
It was a bumper year at the annual American Society of Hematology (ASH) meeting, with a slew of new data presented across the board. Here is a round-up of some of the key data presented.
Gilead eyes new first-line indication for CAR T Yescarta
Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential new indication.
Dec 11, 2020
Daratumumab and bortezomib work well with novel conjugate
A high percentage of patients diagnosed with relapsed or refractory multiple myeloma who have been treated with previous lines of therapy responded to investigative aminopeptide conjugate melflufen in combination with dexamethasone and either daratumumab (Darzalex) or bortezomib (Velcade), researchers found.
Among 13 patients treated with melflufen (melphalan flufenamide), bortezomib, and dexamethasone, the overall response rate was 62% (8 patients) four of those eight patients achieved a very good partial response or better, and one achieved a complete response in the ANCHOR trial, reported Enrique Ocio, MD, PhD, head of the department of hematology at University Hospital Marqués de Valdecilla, University of Cantabria, Santander, Spain.
Reimagine Biomedical Research for a Healthier Future: Essay Challenge
Reimagine Biomedical Research for a Healthier Future Essay Challenge.
The biomedical research enterprise experienced a year of reckoning in 2020. Global cooperation to create a COVID-19 vaccine at an unprecedented pace shows the promise of research. Yet the pandemic, the resulting economic and social uncertainties, and the urgency of addressing systemic racial and regional inequities all add to longstanding concerns about the sustainability of the biomedical research enterprise. We need a new vision for a healthier future. The
Reimagine Biomedical Research for a Healthier Future Essay Challenge is your opportunity to propose systemic changes that re-commit to serving society and achieving an equitable, diverse, and creative environment for
Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.